Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37686
Title: Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial
Authors: Ploumen, EH
Buiten, RA
Zocca, P
Doggen, CJM
Jessurun, GAJ
Schotborgh, CE
Roguin, A
Danse, PW
BENIT, Edouard 
Aminian, A
Anthonio, RL
Somi, S
Linssen, GCM
Hartmann, M
Kok, MM
von Birgelen, C
Issue Date: 2021
Publisher: WILEY
Source: Catheterization and cardiovascular interventions, 98 (2) , p. E188 -E196
Abstract: Objectives To compare 2-year outcome following treatment with drug-eluting stents (DES) for acute myocardial infarction (MI) versus non-MI clinical syndromes. In acute MI patients, a stent-level comparison was performed, comparing Resolute Onyx versus Orsiro stents.Background In patients presenting with acute MI, higher adverse event rates have been reported. So far, no clinical results >1 year have been published of acute MI patients treated with Resolute Onyx.Methods This post-hoc analysis of the randomized BIONYX trial(NCT02508714) assessed the main outcome target vessel failure (TVF: cardiac death, target vessel MI, or target vessel revascularization) with Kaplan-Meier methods.Results Of all 2,488 trial participants, acute MI patients (n = 1,275[51.2%]) were significantly younger and had less comorbidities than non-MI patients (n = 1,213[48.8%]). TVF rates were lower in acute MI patients (77/1,275[6.1%] vs. 103/1,213[8.6%], HR:0.70, 95%-CI 0.52-0.94; p(log-rank) = 0.02), mainly driven by target vessel revascularization (4.1 vs. 6.1%, p(log-rank) = 0.03). Multivariate analysis showed no independent association of clinical syndrome with TVF (adjusted-HR: 0.81, 95%-CI 0.60-1.10; p = .17). In MI patients treated with Resolute Onyx (n = 626) versus Orsiro (n = 649), there was no difference in TVF (6.2 vs. 6.1%; p(log-rank) = 0.97) and its components. There was only 1(0.2%) definite-or-probable stent thrombosis in RO-ZES and 8(1.2%) in O-SES (p = .053).Conclusions Two years after treatment with thin-strut DES in this randomized trial, patients treated for acute MI had lower adverse event rates than non-MI patients. Yet, these findings were mainly attributable to between-group differences in patient and lesion characteristics. In patients who underwent PCI for acute MI, both Resolute Onyx and Orsiro showed favorable and similar 2-year outcomes.
Keywords: clinical trials;drug‐eluting stent;myocardial infarction;percutaneous coronary intervention
Document URI: http://hdl.handle.net/1942/37686
ISSN: 1522-1946
e-ISSN: 1522-726X
DOI: 10.1002/ccd.29594
ISI #: 000627272100001
Rights: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.